NasdaqGS:BIOAPharmaceuticals
BioAge Labs (BIOA) Heavy Quarterly Loss Reinforces Bearish Community Narrative On Profitability
BioAge Labs (BIOA) just posted its FY 2025 third quarter numbers, reporting revenue of US$2.1 million and a basic EPS loss of US$0.56, alongside a net loss of US$20.2 million, keeping the story firmly in loss-making territory. Over recent quarters, revenue has moved from US$0 million in Q4 2024 to US$1.5 million in Q1 2025 and US$2.4 million in Q2 2025. Quarterly basic EPS has remained in loss-per-share territory between US$0.36 and US$0.60, which keeps the focus on the pace at which losses...